Evidence map›Paper›PMID 42846607›Full record

ArticleFrontiers in pharmacology2026

Cenobamate in Dravet syndrome with electrophysiologically confirmed

Pascal Fenske, Astghik Abrahamyan, Konstantin L Makridis, Sabrina Pommer, Thorsten Trimbuch, Anna-Lena Friedo, Christoph Kellinghaus, Florian-Phillipp Losch, Bettina Schmitz, Christian Boßelmann and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Pascal Fenske *Department of Pediatric Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Astghik Abrahamyan *Institute of Neurophysiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Konstantin L MakridisDepartment of Pediatric Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Sabrina PommerDepartment of Pediatric Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Thorsten TrimbuchInstitute of Neurophysiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Anna-Lena FriedoEpilepsieklinik Tabor, Bernau, Germany.
Christoph KellinghausEpilepsy Center Münster-Osnabrück, Klinikum Osnabrück, Osnabrück, Germany.
Florian-Phillipp LoschDepartment of Neurology, Vivantes Humboldt-Klinikum, Berlin, Germany.
Bettina SchmitzDepartment of Neurology, Vivantes Humboldt-Klinikum, Berlin, Germany.
Christian BoßelmannDepartment of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.
Shyamala ManiDepartment of Pediatric Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Christian RosenmundInstitute of Neurophysiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Angela M KaindlDepartment of Pediatric Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy (DEE) characterized by seizures and developmental delay/regression, primarily caused by loss-of-function (LoF) variants in the

Indexed as

anti-seizure medicationcenobamatedevelopmental and epileptic encephalopathyDravet syndromeepilepsy

Identifiers

PMID42846607
PMCPMC13643072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.